{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:44:10Z","timestamp":1794541450018,"version":"4.9.1"},"reference-count":184,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    CD19 chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of relapsed\/refractory B-cell malignancies, achieving high remission rates. Nonetheless, 20%-40% of patients eventually relapse, classified as either CD19\n                    <jats:sup>+<\/jats:sup>\n                    or CD19\n                    <jats:sup>\u2212<\/jats:sup>\n                    relapse. Most relapses are CD19\n                    <jats:sup>+<\/jats:sup>\n                    , largely due to reduced potency and poor persistence of CAR-T cells after infusion. In contrast, a substantial fraction of patients develops CD19\n                    <jats:sup>\u2212<\/jats:sup>\n                    relapse driven by selective pressure from CAR-T cell therapy. Post-CAR-T cell CD19\n                    <jats:sup>\u2212<\/jats:sup>\n                    relapse primarily arises through three mechanisms. First, pre-existing CD19\n                    <jats:sup>\u2212<\/jats:sup>\n                    subclones, particularly those with progenitor-like features, expand because of their survival advantages. Second, CD19 expression is downregulated through pre-existing or newly acquired genetic alterations (mutations and abnormal splicing), epigenetic silencing, and post-transcriptional dysregulation. Third, lineage switching to a myeloid phenotype increases notably after CAR-T cell treatment. This myeloid conversion is frequently associated with KMT2A rearrangements and is driven by epigenetic reprogramming, impaired expression of B-cell regulators, and the presence of bipotent progenitors within leukemia or lymphoma. CD19\n                    <jats:sup>-<\/jats:sup>\n                    relapse constitutes a major clinical barrier to the durable efficacy of CD19-CAR T-cell therapy. Understanding these diverse escape mechanisms is crucial for developing preventive strategies and effective salvage therapies to maintain long-term remission. To mitigate CD19\n                    <jats:sup>-<\/jats:sup>\n                    relapse, a coordinated dual strategy is needed. First, novel therapeutic approaches should be developed, including CAR products targeting alternative antigens, optimized salvage regimens, and CD19 re-induction strategies. Second, high-resolution molecular profiling should be used to identify high-risk patients and guide pre-emptive or combinatorial interventions based on the molecular underpinnings of CD19\n                    <jats:sup>-<\/jats:sup>\n                    relapse. Together, these approaches will deepen mechanistic insight into CD19\n                    <jats:sup>-<\/jats:sup>\n                    relapse and enable targeted prevention and management of this key limitation of CAR T-cell therapy.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1692287","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:28:36Z","timestamp":1775539716000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiawen","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duonan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/s2666-6367(22)00171-3","article-title":"Long-term (\u22654 year and \u22655 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.7010","article-title":"Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL) in ZUMA-3","volume":"40","author":"Shah","year":"2022","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s1470-2045(21)00591-x","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00668","article-title":"Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"43","author":"Neelapu","year":"2025","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000422","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v126.23.684.684","article-title":"Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia","volume":"126","author":"Lee","year":"2015","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.219.219","article-title":"CD19CAR T cell products of defined CD4:CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-cell ALL","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/jci85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v126.23.681.681","article-title":"Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v124.21.380.380","article-title":"T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL","volume":"124","author":"Grupp","year":"2014","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v122.21.67.67","article-title":"T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant In Vivo proliferation, complete responses and long-term persistence without Gvhd in children and adults with relapsed, refractory ALL","volume":"122","author":"Grupp","year":"2013","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/blood.v128.22.217.217","article-title":"Durable remissions with humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in CAR-naive and CAR-exposed children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"130","author":"Maude","year":"2017","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.2801.2801","article-title":"Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis","volume":"128","author":"Maude","year":"2016","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16623","article-title":"Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia","volume":"191","author":"Wang","year":"2020","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26123","article-title":"Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed\/refractory pediatric acute lymphoblastic leukemia","volume":"96","author":"Wang","year":"2021","journal-title":"Am J Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18105","article-title":"Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia","volume":"197","author":"Jacoby","year":"2022","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","article-title":"Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia","volume":"13","author":"Gu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41408-025-01397-4","article-title":"IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial","volume":"15","author":"Xue","year":"2025","journal-title":"Blood Cancer J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014182","article-title":"Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"9","author":"Wang","year":"2025","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1672509","article-title":"Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1205","article-title":"CD19-specific CAR-T cell treatment of 115 children and young adults with acute B lymphoblastic leukemia: long-term follow-up","volume":"56","author":"Wang","year":"2024","journal-title":"Cancer Res Treat"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015314","article-title":"Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naive adult patients with B-ALL","volume":"9","author":"Gauthier","year":"2025","journal-title":"Blood Adv"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1019115","article-title":"CAR-T cell therapy for hematological Malignancies: limitations and optimization strategies","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v63.6.1424.1424","article-title":"Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"Am J Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nm1253","article-title":"Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia","volume":"11","author":"Castor","year":"2005","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v95.3.1007.003k35_1007_1013","article-title":"A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia","volume":"95","author":"Cobaleda","year":"2000","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0901","article-title":"Characterization of acute lymphoblastic leukemia progenitor cells","volume":"104","author":"Cox","year":"2004","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-04-1356","article-title":"Leukemic stem cells in childhood high-risk ALL\/t (9,22) and t (4,11) are present in primitive lymphoid-restricted CD34+CD19- cells","volume":"65","author":"Hotfilder","year":"2005","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ccr.2008.05.015","article-title":"In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties","volume":"14","author":"le Viseur","year":"2008","journal-title":"Cancer Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154187","article-title":"Expression of CD133 on leukemia-initiating cells in childhood ALL","volume":"113","author":"Cox","year":"2009","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21373","article-title":"CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-immunophenotypic challenges in diagnosis and monitoring: a study of three cases","volume":"92","author":"Ghodke","year":"2017","journal-title":"Cytometry B Clin Cytom"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.963579","article-title":"CD19-negative B-lymphoblastic leukemia associated with hypercalcemia, lytic bone lesions and aleukemic presentation","volume":"56","author":"Hussein","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3343\/kjlm.2007.27.4.253","article-title":"A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology","volume":"27","author":"Moon","year":"2007","journal-title":"Korean J Lab Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1625043","article-title":"CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy era","volume":"60","author":"Bommannan","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.203521","article-title":"Molecular analysis of a CD19-negative diffuse large B-cell lymphoma","volume":"104","author":"Delage","year":"2019","journal-title":"Haematologica"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22109","article-title":"CD19 negative diffuse large B-cell lymphoma presenting in leukemic phase","volume":"104","author":"Ramalingam","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"key":"B73","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood.2021014840","article-title":"CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies","volume":"140","author":"Bueno","year":"2022","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22135","article-title":"CD19-negative B-cell precursors in bone marrow: a potential mimicker for CD19-negative B-lymphoblastic leukemia by flow cytometry in patients with anti-CD19 treatment","volume":"104","author":"Li","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17382","article-title":"Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease","volume":"193","author":"Mikhailova","year":"2021","journal-title":"Br J Haematol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cyto.b.22104","article-title":"Circulating CD22+\/CD19-\/CD24- progenitors and CD22+\/CD19+\/CD24- mature B cells: diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia","volume":"104","author":"Zhou","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22159","article-title":"Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-acute lymphoblastic leukemia cases: a potential mimicker of residual disease after anti CD19 therapy","volume":"106","author":"Ramalingam","year":"2024","journal-title":"Cytometry B Clin Cytom"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-3784","article-title":"Modulation of target antigen density improves CAR T-cell functionality and persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70015","article-title":"Clinical impact of CD19 expression assessed by quantitative PCR in lymphoma patients undergoing CAR-T therapy","volume":"6","author":"Hernani","year":"2025","journal-title":"EJHaem"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0760-x","article-title":"Serial evaluation of CD19 surface expression in pediatric B-cell Malignancies following CD19-targeted therapy","volume":"34","author":"Libert","year":"2020","journal-title":"Leukemia"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky946","article-title":"Aberrant splicing in B-cell acute lymphoblastic leukemia","volume":"46","author":"Black","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2023.2184143","article-title":"Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL","volume":"12","author":"Ziegler","year":"2023","journal-title":"Oncoimmunology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-022-31818-y","article-title":"High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance","volume":"13","author":"Cortes-Lopez","year":"2022","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1182\/blood-2023-185074","article-title":"CD19 intron retention is mechanism of CAR-T treatment resistance in non-Hodgkin lymphoma","volume":"142","author":"Noble","year":"2023","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0580-z","article-title":"Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19","volume":"34","author":"Asnani","year":"2020","journal-title":"Leukemia"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1101\/2025.02.28.640707","article-title":"The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies","volume-title":"bioRxiv","author":"Krawczyk","year":"2025"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf1426","article-title":"CD19 CAR antigen engagement mechanisms and affinity tuning","volume":"8","author":"He","year":"2023","journal-title":"Sci Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-5890(97)00144-2","article-title":"Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma","volume":"34","author":"Nicholson","year":"1997","journal-title":"Mol Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.9b00808","article-title":"Fine epitope mapping of the CD19 extracellular domain promotes design","volume":"58","author":"Klesmith","year":"2019","journal-title":"Biochemistry"},{"key":"B96","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12967-024-05254-z","article-title":"Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008977","article-title":"A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia","volume":"7","author":"Masih","year":"2023","journal-title":"Blood Adv"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1038\/s41467-025-58868-2","article-title":"IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell Malignancies","volume":"16","author":"Domizi","year":"2025","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00383-18","article-title":"CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum","volume":"38","author":"Bagashev","year":"2018","journal-title":"Mol Cell Biol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"B102","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4049\/jimmunol.170.1.73","article-title":"CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals","volume":"170","author":"Otero","year":"2003","journal-title":"J Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13059-021-02411-1","article-title":"Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts","volume":"22","author":"Schulz","year":"2021","journal-title":"Genome Biol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-22-0095","article-title":"Characterization of leukemic resistance to CD19-targeted CAR T-cell therapy through deep genomic sequencing","volume":"11","author":"Chen","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15113058","article-title":"Clinical impact of single nucleotide polymorphism in CD-19 on treatment outcome in FMC63-CAR-T cell therapy","volume":"15","author":"Seipel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002352","article-title":"Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro","volume":"9","author":"Ledererova","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1172\/jci175199","article-title":"Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency","volume":"134","author":"Aminov","year":"2024","journal-title":"J Clin Invest"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01314-y","article-title":"NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia","volume":"23","author":"Witkowski","year":"2022","journal-title":"Nat Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41467-022-31035-7","article-title":"Antigen glycosylation regulates efficacy of CAR T cells targeting CD19","volume":"13","author":"Heard","year":"2022","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007705","article-title":"Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies","volume":"6","author":"Ghobadi","year":"2022","journal-title":"Blood Adv"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-21-0626","article-title":"Regulatory programs of B-cell activation and germinal center reaction allow B-ALL escape from CD19 CAR T-cell therapy","volume":"10","author":"Im","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.cir-21-0853","article-title":"Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers","volume":"10","author":"Blanco","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1992622","article-title":"CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas","volume":"63","author":"Fitzgerald","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.21417\/b7v06m","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2011.26.6.829","article-title":"Lineage switch at relapse of childhood acute leukemia: a report of four cases","volume":"26","author":"Park","year":"2011","journal-title":"J Korean Med Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23266","article-title":"Lineage switch in childhood acute leukemia: an unusual event with poor outcome","volume":"87","author":"Rossi","year":"2012","journal-title":"Am J Hematol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-009-0007-3","article-title":"Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse","volume":"15","author":"Imataki","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-024-00983-2","article-title":"Genetics and pathologic landscape of lineage switch of acute leukemia during therapy","volume":"14","author":"Zhou","year":"2024","journal-title":"Blood Cancer J"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1515\/med-2022-0521","article-title":"Lineage switch from lymphoma to myeloid neoplasms: first case series from a single institution","volume":"17","author":"Yang","year":"2022","journal-title":"Open Med (Wars)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27265","article-title":"Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia","volume":"65","author":"Oberley","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15812","article-title":"Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure","volume":"186","author":"Lucero","year":"2019","journal-title":"Br J Haematol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00604-0","article-title":"Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy","volume":"4","author":"Coorens","year":"2023","journal-title":"Nat Cancer"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001563","article-title":"Diagnostic approach to the evaluation of myeloid Malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia","volume":"8","author":"Mo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000000962","article-title":"A report on lineage switch at relapse of CD19 CAR-T therapy for Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia","volume":"133","author":"Li","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02449-7","article-title":"The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients","volume":"39","author":"Qiu","year":"2025","journal-title":"Leukemia"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285574","article-title":"Clonal evolution from B-cell acute lymphoblastic leukemia with BCR::ABL1 multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell therapy","volume":"109","author":"Liu","year":"2024","journal-title":"Haematologica"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1159\/000544038","article-title":"Single-cell transcriptomic analysis of myeloid lineage evolution from CD19 CAR-T cell therapy","volume":"92","author":"Cui","year":"2025","journal-title":"Pathobiology"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018018093","article-title":"Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL","volume":"2","author":"Wolfl","year":"2018","journal-title":"Blood Adv"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23074019","article-title":"Lineage conversion in pediatric B-cell precursor acute leukemia under blinatumomab therapy","volume":"23","author":"Semchenkova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2021.07.002","article-title":"Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia","volume":"100","author":"Liao","year":"2021","journal-title":"Exp Hematol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqad035","article-title":"Phenotypic and genotypic infidelity in B-lineage neoplasms, including transdifferentiation following targeted therapy: report from the 2021 SH\/EAHP Workshop","volume":"159","author":"Goodlad","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2351194","article-title":"Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia","volume":"65","author":"Beldzinska-Gadek","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00081","article-title":"Rewiring the epigenetic networks in MLL-rearranged leukemias: epigenetic dysregulation and pharmacological interventions","volume":"7","author":"Chan","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015036","article-title":"Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukemia","volume":"140","author":"Tirtakusuma","year":"2022","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146102","article-title":"Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia","volume":"139","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009499","article-title":"CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy","volume":"12","author":"Silbert","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713322","article-title":"Relapse\/refractory paediatric B-ALL case with CD19(-) phenotype switching indicating the importance of appropriate diagnostic approach and targeted treatment adjustment-case report","volume":"24","author":"Prazmo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-21-0163","article-title":"ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia","volume":"3","author":"Dickerson","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-23-0106","article-title":"Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis","volume":"5","author":"Saygin","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/ni1454","article-title":"Pax5: the guardian of B cell identity and function","volume":"8","author":"Cobaleda","year":"2007","journal-title":"Nat Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30842","article-title":"A PAX5 P80R pediatric B acute lymphoblastic leukemia with monocytic lineage switch at diagnosis: Deciphering classification ambiguity","volume":"71","author":"Strullu","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.250423","article-title":"DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch","volume":"106","author":"Novakova","year":"2021","journal-title":"Haematologica"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009515","article-title":"Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy","volume":"138","author":"Wudhikarn","year":"2021","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.08.030","article-title":"INSPIRED Symposium Part 2: Prevention and management of relapse following chimeric antigen receptor T cell therapy for B cell acute lymphoblastic leukemia","volume":"29","author":"Lamble","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279677","article-title":"Immunophenotypic changes in leukemic blasts in children with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)-expressing T cells","volume":"107","author":"Mikhailova","year":"2022","journal-title":"Haematologica"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2230888","article-title":"Blinatumomab as salvage therapy in patients with relapsed\/refractory B-ALL who have failed\/progressed after anti-CD19-CAR T therapy","volume":"55","author":"Qi","year":"2023","journal-title":"Ann Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-7810","article-title":"Inotuzumab ozogamicin as salvage therapy for refractory\/relapsed B-cell acute lymphoblastic leukemia following the failure of chimeric antigen receptor T cell therapy and allogeneic hematopoietic stem cell transplantation","volume":"146","author":"Li","year":"2025","journal-title":"Blood"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol Rep"},{"key":"B161","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/jco.24.00826","article-title":"Menin inhibition with Revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"TPS2671","DOI":"10.1200\/jco.2024.42.16_suppl.tps2671","article-title":"ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors","volume":"42","author":"Palmer","year":"2024","journal-title":"J Clin Oncol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009480","article-title":"Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1797","article-title":"Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing\/reactivation of the EBF\/Pax5 pathway","volume":"101","author":"Yu","year":"2003","journal-title":"Blood"},{"key":"B165","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41408-024-01105-8","article-title":"Bispecific CAR-T cells targeting CD19\/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I\/II trial","volume":"14","author":"Wang","year":"2024","journal-title":"Blood Cancer J"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell Malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B171","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19370","article-title":"Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia","volume":"204","author":"Bommannan","year":"2024","journal-title":"Br J Haematol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02580-z","article-title":"LILRB1-directed CAR-T cells for the treatment of hematological Malignancies","volume":"39","author":"Marhelava","year":"2025","journal-title":"Leukemia"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1172\/jci87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell Malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-023-01853-1","article-title":"Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model","volume":"28","author":"Ba","year":"2023","journal-title":"Apoptosis"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26787","article-title":"The feasibility of additional CD19-targeted cellular therapy in relapsed\/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse","volume":"98","author":"Agrawal","year":"2023","journal-title":"Am J Hematol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378739","article-title":"CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"B181","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1692287\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:28:38Z","timestamp":1775539718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1692287\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":184,"alternative-id":["10.3389\/fimmu.2026.1692287"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1692287","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"article-number":"1692287"}}